PNC Financial Services Group’s Nautilus Biotechnolgy NAUT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
– Sell
-3,966
Closed -$3.42K – 5016
2025
Q1
$3.42K Buy
3,966
+3,934
+12,294% +$5.85K ﹤0.01% 4188
2024
Q4
$54 Buy
+32
New +$77 ﹤0.01% 4733
2024
Q1
– Sell
-11
Closed -$33 – 4773
2023
Q4
$33 Sell
11
-533
-98% -$1.52K ﹤0.01% 4586
2023
Q3
$1.72K Hold
544
– – ﹤0.01% 4281
2023
Q2
$2.11K Sell
544
-98
-15% -$282 ﹤0.01% 4365
2023
Q1
$1.78K Hold
642
– – ﹤0.01% 4337
2022
Q4
$1.16K Sell
642
-55
-8% -$106 ﹤0.01% 4379
2022
Q3
$2K Buy
697
+55
+9% +$138 ﹤0.01% 4196
2022
Q2
$2K Buy
+642
New +$2.39K ﹤0.01% 4227
2022
Q1
– Sell
-3,000
Closed -$16K – 4645
2021
Q4
$16K Buy
+3,000
New +$16.1K ﹤0.01% 3630

Other funds holding NAUT

PNC Financial Services Group's NAUT Position: Q2 2025 in Review

PNC Financial Services Group sold out of Nautilus Biotechnolgy (NAUT) in Q2 2025, closing a stake of 3,966 shares — an estimated $3.42K sold.

PNC Financial Services Group first reported a position in NAUT in Q4 2021 and held it in 10 quarters. The position peaked at $16K in Q4 2021. 71 funds tracked by Wall St. Rank hold NAUT as of Q2 2025.

  • PNC Financial Services Group reported no remaining Nautilus Biotechnolgy position as of Q2 2025 after selling out during the quarter.
  • PNC Financial Services Group sold 3,966 Nautilus Biotechnolgy shares in Q2 2025, an estimated $3.42K.
  • PNC Financial Services Group first reported a position in Nautilus Biotechnolgy in Q4 2021 and held it in 10 quarters.
  • PNC Financial Services Group's Nautilus Biotechnolgy position peaked at $16K in Q4 2021.
  • 71 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2025.

Based on PNC Financial Services Group's 13F filing for Q2 2025, filed 8 Aug 2025.